Company Dossier · Health Care
Cooper Companies (The)
- S&P 500
- Russell 1000
What Cooper Companies (The) is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to July 31, 2026: $4.24 billion, up 4.7% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to July 31, 2026: $0.68 billion, up 66% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to July 31, 2026: $0.36 billion, down 10% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to October 31, 2025: $0.29 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to October 31, 2025: $3.11 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (September 9, 2026): sentiment -0.20 on a −1 to +1 scale (negative), confidence 0.60 of 1.Palanor Discourse
- Guidance in the last 90 days: 0 outlook figures raised, 1 lowered, 1 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed December 5, 2025): 0 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net buyers in Q3 2026: $1.9 million on the open market.SEC Form 4
- 674 institutional managers reported a position at June 30, 2026 (+1 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 10 (7 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, Jul 30, 2026 →
Company Posture
How Company Posture is measured →What Cooper Companies (The) is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Hedging
Expanding ↔ Retrenching
Steady
- Capital spending16th pct
- Debt raised94th pct
- Buybacks vs capex30th pct
- Hiring filings68th pct
- Deals and private raises49th pct
- Patent publications6th pct
Confident ↔ Hedging
Hedging
- Call sentiment9th pct
- Call confidence12th pct
- Guidance changes8th pct
- Risk factors added74th pct
- Insider open-market trades78th pct
- − Guidance changes
- − Call sentiment
- − Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver45th pct
- Stress filings48th pct
Credit
How these are built →Cooper Companies (The)'s borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$2.5B
- Due within a year $0.6B
- Longer term $1.9B
- Default point $1.6B (short + ½ long)
Finance leases included · Jul 31, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026Patent
- Oct 19, 2026LobbyingLobbying report (THORN RUN PARTNERS)third_quarter 2026 · $0.1 million
- Sep 15, 2026Patent
- Sep 15, 2026PatentPatent granted: CONTACT LENS BLISTER PACKAGEUS 12735238
- Jul 30, 2026Risk event
- Jul 28, 2026Patent
- Jul 28, 2026Patent
- Jul 20, 2026LobbyingLobbying report (THORN RUN PARTNERS)second_quarter 2026 · $0.1 million
- May 4, 20268-KDirector or officer changeItem 5.02
- Apr 18, 2026LobbyingLobbying report (THORN RUN PARTNERS)first_quarter 2026 · $0.1 million
- Apr 8, 20268-KShareholder vote resultsItem 5.07
- Feb 4, 20268-KMaterial agreement signedItem 1.01
- Jan 21, 2026LobbyingLobbying report (THORN RUN PARTNERS)fourth_quarter 2025 · $0.1 million
- Jan 19, 2026LobbyingLobbying report (THORN RUN PARTNERS)fourth_quarter 2025 · $0.1 million
- Dec 23, 20258-KMaterial agreement signedItem 1.01
- Dec 23, 20258-KDirector or officer changeItem 5.02
- Dec 12, 20258-KDirector or officer changeItem 5.02
- Dec 5, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Dec 4, 20258-KDirector or officer changeItem 5.02
- Oct 20, 2025LobbyingLobbying report (THORN RUN PARTNERS)third_quarter 2025 · $0.1 million
- Jul 17, 2025LobbyingLobbying report (THORN RUN PARTNERS)second_quarter 2025 · $0.1 million
- May 20, 2025Risk event
- Apr 30, 20258-KDirector or officer changeItem 5.02
- Apr 17, 2025LobbyingLobbying report (THORN RUN PARTNERS)first_quarter 2025 · $0.1 million
- Apr 2, 20258-KShareholder vote resultsItem 5.07
- Feb 5, 20258-KDirector or officer changeItem 5.02
- Dec 6, 202410-KAnnual report (10-K)1 risk factors added, 1 removed
- Dec 8, 202310-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Align Technology ALGN | $4.1B | $0.6B | Jun 30, 2026 |
| West Pharmaceutical Services WST | $3.3B | $0.4B | Jun 30, 2026 |
| Envista NVST | $2.9B | $0.3B | Jul 3, 2026 |
| Mettler Toledo MTD | $4.1B | $0.9B | Jun 30, 2026 |
| Illumina, Inc. ILMN | $4.5B | $0.9B | Jun 28, 2026 |
| Charles River Laboratories CRL | $4.0B | $0.4B | Jun 27, 2026 |
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| Jazz Pharmaceuticals JAZZ | $4.6B | $1.6B | Jun 30, 2026 |